Brainstorm Cell Therapeutics's total assets for Q2 2025 were $2.57M, a decrease of -28.14% from the previous quarter. BCLI total liabilities were $8.62M for the fiscal quarter, a -21.81% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.